COVID-19 Active Infection Test
Who is getting tested? *
Currently you cannot combine this test with other tests. Because of this, you cannot buy this test unless you update your cart.
Currently you can only purchase testing for one person in one cart checkout. Or product(s) cannot be purchased because you do not meet the age, gender, or location requirements to purchase the test(s).
Because of this, you cannot buy this test unless you update your cart or account setting(s).
This product contains duplicate test components to items in your cart. You are already covered by a test that you have in the cart.
Additionally, COVID-19 tests cannot be combined with other tests at this time.
Please update your cart before you try again.
Based on your response, this test is not right for you or not available.
This test is unavailable for your age and/or gender.
Please update your address
Quest does not currently support lab testing at your location, please update to a valid address to purchase this test.
Visit Account Settings to change your address.
Please select who is getting tested.
Please select test type.
Anterior nares (nasal) swab collection kit with in-person and at-home collection options.
In-person: a healthcare professional will observe while you complete the self-collection process yourself inside the location or in your vehicle
the number and reach within the USA.
the number and reach within the USA.
The benefits of testing
You can get the information you need to support a healthy life - for yourself.
Take control of your health
Conveniently shop and pay online for lab tests without a doctor's visit. An independent physician will review your request and if appropriate, confirm your order and offer oversight.
Schedule and manage your appointments
Conveniently schedule your appointment online at one of our Quest Patient Service Centers or drive-through locations. Certain tests may also offer self-testing home delivery.
Get your results online
View your results through your secure account online. And it's easy to share the result with your doctor.
The IgG and IgM antibody tests are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS CoV-2 antibodies. IgG and IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARSCoV-2 is necessary. The tests should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the test may occur due to cross-reactivity from pre-existing antibodies or other possible causes. The sensitivity of the IgM test early after infection is unknown. Due to the risk of false positive results, confirmation of positive results should be considered using a second, different IgM assay or an IgG assay. Samples should only be tested for IgM from individuals with 15 days to 30 days post symptom onset. SARS-CoV-2 antibody negative samples collected 15 days or more post symptom onset should be reflexed to a test that detects and reports SARS-CoV-2 IgG.
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, and influenza B virus, and not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.